Catalog Number
ACM84088426
Description
Roquinimex (Linomide; PNU212616; ABR212616) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity; inhibits angiogenesis and reduces the secretion of TNF alpha.IC50 value:Target: TNF alphaProphylactic administration of DSS-treated mice with roquinimex significantly reduced clinical signs of colitis, MDS and the CH-reduction. Moreover, in roquinimex treated animals, the MPO activity was significantly reduced by more than 50% compared to DSS control mice. Notably, therapeutic administration of roquinimex in DSS-treated mice also significantly inhibited the MDS, CH-reduction and MPO activity . Linomide, a synthetic immunomodulator, at concentrations effective in vivo reduces the number of MBP-reactive TNF-alpha and increases MBP-reactive IL-10 and TGF-beta mRNA expressing MNC from MS patients' blood when analysed in vitro. Compared to dexamethasone, Linomide up-regulated levels of blood MNC expressing mRNA of TGF-beta after culture in presence of MBP .
Synonyms
N-PHENYLMETHYL-1,2-DIHYDRO-4-HYDROXYL-N,1-DIMETHYL-2-OXO-QUINOLINE-3-CARBOXAMIDE;ROQUINIMEX;LINOMIDE;LS-2616;1,2-DIHYDRO-4-HYDROXY-N,1-DIMETHYL-2-OXO-N-PHENYL-3-QUINOLINECARBOXAMIDE;1,2-DIHYDRO-4-HYDROXY-N,N-DIMETHYL-2-OXO-N-PHENYL-3-QUINOLINECARBOXAMIDE;4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide;1,2-Dihydro-4-hydroxy-1,N-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide
Molecular Formula
C18H16N2O3
Canonical SMILES
O=C(C1=C(O)C2=C(N(C)C1=O)C=CC=C2)N(C)C3=CC=CC=C3
Storage
Powder-20°C, 3 years; 4°C, 2 years; In solvent-80°C, 6 months; -20°C, 1 month.
Shipping
Can be shipped at room temperature, where not in use may vary.
Supplemental Hazard Statements
H302
Download
